{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"ORR will be defined as complete response + partial response and assessed by Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Ulixertinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of treatment, up to 2 years","title":"Objective Response Rate (ORR = Complete Response [CR] + Partial Response [PR]) in Pediatric Patients Treated With BVD-523FB (Ulixertinib)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}